Características de los glóbulos rojos asociadas a la trombosis venosa relacionada con vectores adenovirales

Adenoviral vector vaccines were pivotal for COVID-19 control, but postmarketing safety surveillance has identified venous-predominant thrombotic risks not fully explained by platelet-centric mechanisms. We tested an RBC-associated hypothesis using an Ad5 vector-rAd/HA(PR8) rat model within a predefined sub-hemolytic window (<10% hemolysis). Ex vivo, we quantified RBC surface phosphatidylserine (PS) exposure, morphology remodeling by scanning electron microscopy, and microvesicle generation, all aligning with increased procoagulant activity. RBCs also exhibited dose-dependent increases in thrombin generation 4 h after intravenous exposure (10⁸-10⁹ OPU/Rat). In vivo, an inferior vena cava thrombosis model showed a pronounced, dose-responsive rise in thrombus burden, consistent with increased thrombogenic potential. Together, these integrated data provide experimental evidence consistent with RBC involvement under adenoviral exposure, supporting a biologically plausible link to the venous-predominant epidemiology observed during the COVID-19 vaccination era. Reported clinical adenoviral vaccine doses are of the same order of magnitude as the exposures tested here, supporting translational relevance while not implying inter-species or product equivalence. Incorporating RBC-focused endpoints, including PS exposure, morphology indices, microvesicle counts, and thrombin generation, into preclinical and early clinical assessments may enhance safety evaluation and inform vector design to mitigate venous thrombotic risk.